#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

A Prescription for Improving Drug Formulary Decision Making


article has not abstract


Vyšlo v časopise: A Prescription for Improving Drug Formulary Decision Making. PLoS Med 9(5): e32767. doi:10.1371/journal.pmed.1001220
Kategorie: Policy Forum
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001220

Souhrn

article has not abstract


Zdroje

1. LaingRWaningBGrayAFordNHoenE 2003 25 years of the WHO essential medicines lists: progress and challenges. Lancet 361 1723 1729

2. TylerLSColeSWMayJRMillaresMValentinoMA 2008 ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health Syst Pharm 65 1272 1283

3. Durán-GarcíaESantos-RamosBPuigventos-LatorreFOrtegaA 2011 Literature review on the structure and operation of Pharmacy and Therapeutics Committees. Int J Clin Pharm 33 475 483

4. TierneyMMannsB 2008 Optimizing the use of prescription drugs in Canada through the Common Drug Review. CMAJ 178 432 435

5. OuachiZAllenetBChouchaneNCalopJ 2011 Organisation of the formulary decision-making process at the hospital level: review of the international literature. Pharmacien Hospitalier et Clinicien 46 263 272

6. GalliniAJuillard-CondatBSauxM-CTabouletF 2011 Drug selection in French university hospitals: analysis of formularies for nine competitive pharmacological classes. Br J Clin Pharmacol 72 823 831

7. HollowayK 2003 Drug and therapeutics committees: a practical guide Geneva World Health Organization. Department of Essential Drugs and Medicines Policy

8. SimonGEPstatyBMMoraM 2005 Principles for evidence-based drug formulary policy. J Gen Intern Med 20 964 968

9. RuckerTD 1982 Formularies: principles, problems, and prognosis. Hosp Pharm 17 460 461

10. GlassmanPAGoodCBKelleyMEBradleyMValentinoM 2001 Physician perceptions of a national formulary. Am J Manag Care 7 241 251

11. BlumenthalDHerdmanR 2000 Description and analysis of the VA National Formulary Washington (D.C.) VA Pharmacy Formulary Analysis Committee, Division of Health Care Services National Academy Press

12. ShrankWHEttnerSLGlassmanPAschSM 2004 A bitter pill: formulary variability and the challenge to prescribing physicians. J Am Board Fam Pract 17 401 407

13. RuckerTDSchiffG 1990 Drug formularies: myths-in-formation. Med Care 28 928 942

14. BruzekRJDullingerD 1992 Drug formulary: the cornerstone of a managed pharmacy program. Journal of Pharmacy Practice 5 75 81

15. RosenauPVLalLSGlasserJH 2009 U.S. pharmacy policy: a public health perspective on safety and cost. Soc Work Public Health 24 543 567

16. TriceSDevineJMistryHMooreELintonA 2009 Formulary management in the Department of Defense. J Manag Care Pharm 15 133 146

17. AveryAJWalkerBHeronTTeasdaleSJ 1997 Do prescribing formularies help GPs prescribe from a narrower range of drugs? A controlled trial of the introduction of prescribing formularies for NSAIDs. Br J Gen Pract 47 810 814

18. MoraMW 2010 How P&T committees can be effective change agents: part 1. Am J Pharm Benefits 2 99 100

19. ShrankWH 2009 Change we can believe in: requiring better evidence for formulary coverage. Am J Pharm Benefits 1 134 136

20. RuckerTD 1999 A public-policy strategy for drug formularies: preparation or procrastination? Am J Health Syst Pharm 56 2338 2342

21. ChrenMMLandefeldCS 1994 Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 271 684 689

22. The Special Committee of Attorneys General 2009 The Consumer & Prescriber Grant Program. Available: http://www.consumerprescribergrantprogram.org/. Accessed 18 April 2012

23. Centers for Education & Research on Therapeutics (CERTs). Available: http://certs.hhs.gov/. Accessed 25 February 2012

24. GrissingerM 2008 The truth about hospital formularies, part 1: we've come a long way—or have we? P T 33 441

25. GrissingerM 2008 The truth about hospital formularies, part 2: survey shows many myths still exist years later. P T 33 504 510

26. Institute of Medicine 2009 Initial national priorities for comparative effectiveness. research report brief Washington (D.C.) National Academy Press

27. SchneeweissS 2007 Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 82 143 156

28. SchiffGDGalanterWL 2009 Promoting more conservative prescribing. JAMA 301 865 867

29. SchiffGDGalanterWLDuhigJLodolceAEKoronkowskiMJ 2011 Principles of conservative prescribing. Arch Intern Med 171 1433 1440

30. FuldaTRWertheimerAI 2007 Handbook of pharmaceutical public policy Binghampton (New York) Hayward Press

31. ShrankWHAschSMAdamsJSetodjiCKerrEA 2006 The quality of pharmacologic care for adults in the United States. Med Care 44 936 945

32. Foundation for Managed Care Pharmacy 2009 AMCP Format for Formulary Submissions Ver 3.0. October 2009. Available: http://www.amcp.org/FmcpCategory.aspx?id=9166. Accessed 18 April 2012

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2012 Číslo 5
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#